EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

dc.contributor.author

Hoimes, Christopher

dc.date.accessioned

2020-07-01T13:57:35Z

dc.date.available

2020-07-01T13:57:35Z

dc.date.updated

2020-07-01T13:57:34Z

dc.identifier.uri

https://hdl.handle.net/10161/21107

dc.title

EV-103: Initial results of enfortumab vedotin plus pembrolizumab for locally advanced or metastatic urothelial carcinoma

dc.type

Conference

duke.contributor.orcid

Hoimes, Christopher|0000-0001-8980-2410

pubs.organisational-group

School of Medicine

pubs.organisational-group

Medicine, Medical Oncology

pubs.organisational-group

Duke

pubs.organisational-group

Medicine

pubs.organisational-group

Clinical Science Departments

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2019 ESMO Enfortumab and pembrolizumab in urothelial cancer.pdf
Size:
66.62 KB
Format:
Adobe Portable Document Format